Investigation of differentially expressed genes that contribute to therapeutic effects of bevacizumab in BRAF mutant melanoma
<p>Malignant melanoma is a highly aggressive and often lethal disease. In 2012, patient outcomes were poor after resection of high-risk stage II and III melanoma, and vascular endothelial growth factor (VEGF) has been implicated in melanoma progression. The phase III AVAST-M clinical trial (r...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Thesis |
| Language: | English |
| Published: |
2020
|
| Subjects: |